Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

How I treat paroxysmal nocturnal hemoglobinuria
Robert A. Brodsky
Blood (2021) Vol. 137, Iss. 10, pp. 1304-1309
Open Access | Times Cited: 141

Showing 1-25 of 141 citing articles:

Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition
Rosario Notaro, Lucio Luzzatto
New England Journal of Medicine (2022) Vol. 387, Iss. 2, pp. 160-166
Closed Access | Times Cited: 70
Approach to the diagnosis of aplastic anemia
Amy E. DeZern, Jane E. Churpek
Blood Advances (2021) Vol. 5, Iss. 12, pp. 2660-2671
Open Access | Times Cited: 61
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria
Phillip Scheinberg, Diego V. Clé, Jin Seok Kim, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 9, pp. 1757-1767
Closed Access | Times Cited: 13
COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria
Gloria F. Gerber, Xuan Yuan, Jia Yu, et al.
Blood (2021) Vol. 137, Iss. 26, pp. 3670-3673
Open Access | Times Cited: 42
Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature
Bruno Fattizzo, Raffaella Pasquale, Valentina Bellani, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 42
The Rational Use of Complement Inhibitors in Kidney Diseases
Fádi Fakhouri, Nora Schwotzer, Déla Golshayan, et al.
Kidney International Reports (2022) Vol. 7, Iss. 6, pp. 1165-1178
Open Access | Times Cited: 30
Molecular pharmacology in complement‐mediated hemolytic disorders
Marta Bortolotti, Wilma Barcellini, Bruno Fattizzo
European Journal Of Haematology (2023) Vol. 111, Iss. 3, pp. 326-336
Open Access | Times Cited: 18
Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043 patient/years analysis
Carmelo Gurnari, Hussein Awada, Simona Pagliuca, et al.
Blood (2024) Vol. 144, Iss. 2, pp. 145-155
Closed Access | Times Cited: 7
Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy
Francesco Versino, Bruno Fattizzo
International Journal of Laboratory Hematology (2024) Vol. 46, Iss. S1, pp. 43-54
Open Access | Times Cited: 7
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria
Bo Xu, Bo Seung Kang, Jixiang Chen, et al.
Blood Reviews (2024) Vol. 66, pp. 101210-101210
Closed Access | Times Cited: 6
Neutrophil diversity and function in health and disease
F Zhang, Yidan Xia, Jiayang Su, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
Thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): Real world data of a Greek nationwide multicenter retrospective study
S. Chatzileontiadou, E. Hatjiharissi, M. Angelopoulou, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 14
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study
Christopher J. Patriquin, Andrija Bogdanović, Morag Griffin, et al.
Advances in Therapy (2024) Vol. 41, Iss. 5, pp. 2050-2069
Open Access | Times Cited: 5
Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria
Régis Peffault de Latour, Morag Griffin, Richard Kelly, et al.
Blood Advances (2024) Vol. 8, Iss. 11, pp. 2718-2725
Open Access | Times Cited: 5
Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings
Richard J. Kelly, Hisakazu Nishimori, Regina Horneff, et al.
Research and Practice in Thrombosis and Haemostasis (2024) Vol. 8, Iss. 4, pp. 102416-102416
Open Access | Times Cited: 5
Paroxysmal nocturnal hemoglobinuria and eculizumab
Lucio Luzzatto, Antonio M. Risitano, Rosario Notaro
Haematologica (2010) Vol. 95, Iss. 4, pp. 523-526
Open Access | Times Cited: 65
Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience
Sophie de Guibert, Régis Peffault de Latour, Nathalie Varoqueaux, et al.
Haematologica (2011) Vol. 96, Iss. 9, pp. 1276-1283
Open Access | Times Cited: 50
Expanding Horizons in Complement Analysis and Quality Control
Ashley Frazer‐Abel, Michael Kirschfink, Zoltán Prohászka
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 28
Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia
Bruno Fattizzo, Marta Bortolotti, Juri Alessandro Giannotta, et al.
Journal of Thrombosis and Haemostasis (2022) Vol. 20, Iss. 8, pp. 1852-1858
Open Access | Times Cited: 21
Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations
Monika Oliver, Christopher J. Patriquin
Journal of Blood Medicine (2023) Vol. Volume 14, pp. 613-628
Open Access | Times Cited: 12
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long‐term results from the phase I/II COMPOSER trial
Alexander Röth, Satoshi Ichikawa, Yoshikazu Ito, et al.
European Journal Of Haematology (2023) Vol. 111, Iss. 2, pp. 300-310
Open Access | Times Cited: 11
Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria
David Dingli, Carlos de Castro, Jamie Koprivnikar, et al.
Hematology (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 4
A Review of Key Regulators of Steady-State and Ineffective Erythropoiesis
Ioana Țichil, Ileana Mitre, Mihnea Zdrenghea, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 9, pp. 2585-2585
Open Access | Times Cited: 4
What is the role of complement in bystander hemolysis? Old concept, new insights
Paschalis Evangelidis, Nikolaos Evangelidis, Efthymia Vlachaki, et al.
Expert Review of Hematology (2024) Vol. 17, Iss. 4-5, pp. 107-116
Closed Access | Times Cited: 4
Особенности метаболизма железа у пациентов с пароксизмальной ночной гемоглобинурией: результаты одноцентрового амбиспективного клинического исследования
Vitalii D. Latyshev, K. A. Lukina, А. А. Соловьева, et al.
Clinical oncohematology (2025) Vol. 18, Iss. 1, pp. 1-9
Open Access
Page 1 - Next Page

Scroll to top